Robert Sergott, MD
Neuro-ophthalmology · Philadelphia, PANPI 1285634105
Payments from drug & device makers
Across 1,563 payments — averaging $970.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$498K
- Mallinckrodt Hospital Products Inc.$303K
- Biogen$232K
- Mallinckrodt Enterprises LLC$71K
- Johnson & Johnson$64K
- EMD Serono, Inc.$60K
- plus $288K from 26 others
Across 21 payments — averaging $550.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$8K
- F. Hoffmann-la Roche AG$3K
- EMD Serono, Inc.$614
What the payments were for
- Consulting fees$199,23913%
- Speaking & faculty fees$1,099,27674%
- Travel & lodging$145,01310%
- Food & beverage$33,2882%
- Education$3730%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 552 | $497,852 |
| Mallinckrodt Hospital Products Inc. | 166 | $303,423 |
| Biogen | 211 | $232,099 |
| Mallinckrodt Enterprises LLC | 46 | $70,768 |
| Johnson & Johnson(2 entities) | 74 | $64,192 |
| EMD Serono, Inc. | 129 | $59,741 |
| Novartis | 119 | $54,170 |
| Astrazeneca UK Limited | 8 | $35,694 |
| AstraZeneca(2 entities) | 24 | $34,630 |
| Bristol Myers Squibb | 62 | $29,669 |
| Argenx US, Inc. | 33 | $27,701 |
| E.r. Squibb & Sons, L.L.C. | 19 | $27,034 |
| F. Hoffmann-la Roche AG | 11 | $26,847 |
| Merck | 10 | $12,964 |
| Genentech, Inc. | 10 | $12,342 |
| GSK | 2 | $6,500 |
| Akebia Therapeutics Inc | 2 | $6,000 |
| Thrombogenics, Inc. | 1 | $5,250 |
| Sanofi | 15 | $5,122 |
| Janssen Scientific Affairs, LLC | 1 | $1,620 |
| Catalyst Pharmaceuticals, Inc. | 1 | $1,200 |
| Genentech USA, Inc. | 30 | $617 |
| ANI Pharmaceuticals, Inc. | 11 | $221 |
| Heidelberg Engineering, Inc. | 5 | $207 |
| UCB, Inc. | 9 | $185 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Eisai Inc. | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| TG Therapeutics, Inc. | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Rapid Pathogen Screening, Inc. | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuro-ophthalmology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 22 | $28,526 |
| LumiganBimatoprost | 16 | $9,666 |
| Pyridostigmine Bromide | 71 | $5,463 |
| Latanoprost | 196 | $3,051 |
| Prednisone | 58 | $419 |
| Ketorolac Tromethamine | 14 | $280 |
| Brimonidine Tartrate | 32 | $262 |
| Dorzolamide Hcl | 16 | $238 |
| Pantoprazole Sodium | 12 | $174 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in Philadelphia
- Adam DebuskPhiladelphia$5.8M
- Madhura TamhankarPhiladelphia$408K
- Mark MosterPhiladelphia$53K
- Kenneth ShindlerPhiladelphia$23K
- Gil BinenbaumPhiladelphia$16K
- Shruthi Harish BindiganavilePhiladelphia$755
- Ramya GnanarajPhiladelphia$459
- Peter MortensenPittsburgh$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.